Therapeutic Drug Repurposing, Repositioning and Rescue Part IV: Financial model and analysis By David M. Kauppi and Dr Stephen Naylor There is a growing consensus that Drug Repurposing, Repositioning and Rescue (DRPx) impacts all stakeholders involved in the therapeutic drug sector. In… Read More
The California Institute for Regenerative Medicines Human iPSC Initiative By Dr Thomas J. Novak This article discusses large-scale generation of patient-derived induced pluripotent stem cells (iPSCs) to accelerate the understanding of disease biology and drug discovery. In 2012, the California Institute for Regenerative Medicine… Read More
mRNA Will Revolutionise the Biopharmaceutical Industry By Dr Ingmar Hoerr Messenger RNA (mRNA) – the naturally occurring molecule honed over thousands of years of evolution to translate accurately and efficiently the information encoded in a cell’s DNA into the proteins essential for maintaining cell function and ensuring an… Read More
Therapeutic Drug Repurposing, Repositioning and Rescue Part III: Market exclusivity using Intellectual Property and regulatory pathways By Dr Stephen Naylor, David M. Kauppi and Judge M. Schonfeld There is a growing consensus that Drug Repurposing, Repositioning and Rescue (DRPx) can impact the prescription drug industry for all concerned… Read More
Therapeutic Drug Repurposing, Repositioning and Rescue Part I: Overview By Dr Stephen Naylor & Judge M. Schonfeld The pharmaceutical industry is still beleaguered by escalating costs, stagnant productivity and protracted timelines as it struggles to bring therapeutic drugs to market. This situation has been compounded by a ravenous… Read More
Collaboration For Innovation Is The New Mantra For The Pharmaceutical Industry By Professor Jackie Hunter In order to maintain a flow of innovative medicines there is a growing realisation that companies cannot allow the status quo to remain as it is and the need to identify sources of… Read More
Highlights from GlobalData’s CRO Benchmark Report By Adam M. Dion The biopharmaceutical industry is currently facing significant headwinds. The blockbuster era is over, development costs are skyrocketing, uncertainty exists around regulatory and reimbursement, patent cliffs, generic erosion and a sluggish global economy all have industry executives losing… Read More
Nanobioscience & Nanotechnology: The Future Of Personalised Medicine By Abhishek Gottipati, Joseph M. Sanders and Dr Scott A. Tenenbaum Nanotechnology has been more than a buzz word in the business world for a long time now and has been striding ahead, living up to the hype. Read More
Innovate While Derisking Drug Development: Yes We Can! Taher Abbasi, Pradeep Fernandes, Dr Shireen Vali and Professor Gurkirpal Singh The outlook for the drug industry continues to remain bleak in context of productivity and success rates. In spite of ongoing increase in R&D expenses and technology revolutions in… Read More
The Information Symphony: Data orchestration for a changing industry managing data on a platform for innovation. By Chris Molloy A leading ballet conductor (1) recently told me of courses which he runs for senior business leaders. He allows them to conduct an orchestra: first, very strictly, with close… Read More
Share Share Tweet Email Stem Cell Banks: Investing in the promise of cancer stem cell science Stem Cell Banks: Investing in the promise of cancer stem cell science By Madeline Page and Rosario Isasi The… Read More
Share Share Tweet Email What Are The Obstacles to Innovation in the Pharmaceutical Industry? What Are The Obstacles to Innovation in the Pharmaceutical Industry? The Pistoia Alliance Innovation is a key word throughout the… Read More
By Michael Werner, Morrie Ruffin and Elizabeth West The regenerative medicine market offers phenomenal opportunities for growth in the next few decades. However, there are still major issues to be addressed to enable this nascent industry to truly flourish, especially with regard to investment and the… Read More
Singapore Strengthens Position as Leading Site for Biopharmaceutical R&D By Kian-Teik Beh Globally, pharmaceutical and biotech companies are confronted by an impending patent cliff, while being challenged with declining research and development (R&D) productivity and the need to integrate multidisciplinary scientific capabilities. … Read More
Overcoming the Limitations of Chemical Structure By Dr Andy Vinter, Dr Steve Gardner and Dr Sally Rose The pharmaceutical business has been profoundly hampered by a ubiquitous and unexpected obstacles; the way it draws its chemical compounds. Scientists, patent agents and business decision makers from R&D, safety,… Read More
Building a Robust Portfolio of New Medicines to Combat Malaria By Dr Timothy N.C. Wells Malaria is one of the biggest killers of our time. Current estimates from the World Health Organisation (WHO) suggest that more than 250 million people are at risk worldwide. More significantly, almost… Read More